Mild Alzheimer's disease research hub

A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer's Disease.

This study is testing a new medicine, ABBV-552, for people with mild Alzheimer's disease. Researchers want to see if it's safe, how well it works, and how the body handles it. They will compare different doses against a dummy medicine (placebo).